Laboratory_NN Diagnosis_NN of_IN Visceral_NP Leishmaniasis_NP null_JJ Leishmania_NP infections_NNS are_VBP worldwide_JJ in_IN distribution_NN :_: they_PP are_VBP found_VBN in_IN five_CD continents_NNS ._SENT The_DT disease_NN is_VBZ endemic_JJ in_IN the_DT tropical_JJ and_CC subtropical_JJ regions_NNS of_IN 88_CD countries_NNS ._SENT There_EX are_VBP an_DT estimated_VBN 12_CD million_CD cases_NNS worldwide_JJ ;_: 1.5_CD to_TO 2_CD million_CD new_JJ cases_NNS occur_VBP every_DT year_NN ._SENT Cutaneous_JJ forms_NNS are_VBP most_RBS common_JJ (_( 1_CD to_TO 1.5_CD million_CD cases_NNS per_IN year_NN )_) ,_, representing_VBG 50_CD to_TO 75_CD %_NN of_IN all_DT new_JJ cases_NNS ,_, and_CC 500,000_CD cases_NNS of_IN VL_NP occur_VBP every_DT year_NN ._SENT The_DT geographical_JJ distribution_NN of_IN leishmaniasis_NN is_VBZ limited_VBN to_TO the_DT areas_NNS of_IN natural_JJ distribution_NN of_IN the_DT sandfly_NN ,_, the_DT vector_NN for_IN the_DT disease_NN ._SENT Economic_JJ development_NN ,_, including_VBG widespread_JJ urbanization_NN ,_, deforestation_NN ,_, and_CC development_NN of_IN newer_JJR settlements_NNS ,_, besides_IN migration_NN from_IN rural_JJ to_TO urban_JJ areas_NNS ,_, is_VBZ responsible_JJ for_IN the_DT spread_NN of_IN the_DT sandfly_NN as_IN well_RB the_DT reservoir_NN system_NN of_IN leishmania_NN ._SENT Moreover_RB ,_, the_DT number_NN of_IN new_JJ host_NN populations_NNS ,_, i.e._FW ,_, populations_NNS of_IN immunodeficient_JJ HIV-infected_JJ patients_NNS ,_, is_VBZ increasing_VBG ,_, especially_RB in_IN southern_JJ Europe_NP and_CC Africa_NP ._SENT Leishmania-HIV_NP coinfection_NN is_VBZ regarded_VBN as_IN an_DT emerging_VBG disease_NN especially_RB in_IN southern_JJ Europe_NP ,_, where_WRB 25_CD to_TO 70_CD %_NN of_IN adults_NNS with_IN VL_NP have_VBP AIDS_NP as_IN well_RB ;_: leishmaniasis_NN behaves_VBZ as_IN an_DT opportunistic_JJ infection_NN ,_, and_CC it_PP has_VBZ been_VBN proposed_VBN that_IN it_PP be_VB included_VBN as_IN an_DT AIDS-defining_NP illness_NN ._SENT Moreover_RB ,_, the_DT presence_NN of_IN the_DT leishmania_NN parasite_NN outside_IN the_DT reticuloendothelial_JJ system_NN ,_, e.g._FW ,_, in_IN the_DT peripheral_JJ blood_NN ,_, in_IN HIV-infected_JJ patients_NNS makes_VBZ these_DT patients_NNS a_DT reservoir_NN and_CC source_NN of_IN infection_NN for_IN the_DT vectors_NNS ._SENT The_DT parasite_NN load_NN in_IN peripheral_JJ blood_NN is_VBZ generally_RB so_RB high_JJ that_IN transmission_NN among_IN intravenous_JJ drug_NN users_NNS by_IN use_NN of_IN shared_JJ syringes_NNS has_VBZ also_RB been_VBN demonstrated_VBN ._SENT The_DT resurgence_NN of_IN leishmaniasis_NN ,_, its_PP$ emergence_NN in_IN newer_JJR geographical_JJ areas_NNS and_CC in_IN newer_JJR hosts_NNS ,_, besides_IN changing_VBG the_DT clinical_JJ profile_NN of_IN infected_JJ patients_NNS ,_, has_VBZ put_VBN forward_RB newer_JJR challenges_NNS in_IN the_DT areas_NNS of_IN diagnosis_NN ,_, treatment_NN ,_, and_CC disease_NN control_NN ._SENT The_DT diagnosis_NN of_IN VL_NP is_VBZ complex_JJ because_IN its_PP$ clinical_JJ features_NNS are_VBP shared_VBN by_IN a_DT host_NN of_IN other_JJ commonly_RB occurring_VBG diseases_NNS ,_, such_JJ as_IN malaria_NN ,_, typhoid_JJ ,_, and_CC tuberculosis_NN ;_: many_JJ of_IN these_DT diseases_NNS can_MD be_VB present_JJ along_IN with_IN VL_NP (_( in_IN cases_NNS of_IN coinfection_NN )_) ;_: sequestration_NN of_IN the_DT parasite_NN in_IN the_DT spleen_NN ,_, bone_NN marrow_NN ,_, or_CC lymph_NN nodes_NNS further_RBR complicates_VBZ this_DT issue_NN ._SENT Laboratory_NN diagnosis_NN of_IN leishmaniasis_NN can_MD be_VB made_VBN by_IN the_DT following_NN :_: (_( i_NP )_) demonstration_NN of_IN parasite_NN in_IN tissues_NNS of_IN relevance_NN by_IN light_JJ microscopic_JJ examination_NN of_IN the_DT stained_VBN specimen_NN ,_, in_IN vitro_NN culture_NN ,_, or_CC animal_JJ inoculation_NN ;_: (_( ii_NP )_) detection_NN of_IN parasite_NN DNA_NN in_IN tissue_NN samples_NNS ;_: or_CC (_( iii_NN )_) immunodiagnosis_NN by_IN detection_NN of_IN parasite_NN antigen_NN in_IN tissue_NN ,_, blood_NN ,_, or_CC urine_NN samples_NNS ,_, by_IN detection_NN of_IN nonspecific_JJ or_CC specific_JJ antileishmanial_JJ antibodies_NNS (_( immunoglobulin_NN )_) ,_, or_CC by_IN assay_NN for_IN leishmania-specific_JJ cell-mediated_JJ immunity_NN ._SENT Demonstration_NN and_CC isolation_NN of_IN parasite_NN ._SENT |_SYM The_DT commonly_RB used_VBN method_NN for_IN diagnosing_VBG VL_NP has_VBZ been_VBN the_DT demonstration_NN of_IN parasites_NNS in_IN splenic_JJ or_CC bone_NN marrow_NN aspirate_NN ._SENT The_DT presence_NN of_IN the_DT parasite_NN in_IN lymph_NN nodes_NNS ,_, liver_NN biopsy_NN ,_, or_CC aspirate_JJ specimens_NNS or_CC the_DT buffy_JJ coat_NN of_IN peripheral_JJ blood_NN can_MD also_RB be_VB demonstrated_VBN ._SENT Amastigotes_NNS appear_VBP as_IN round_NN or_CC oval_JJ bodies_NNS measuring_VBG 2_CD to_TO 3_CD mum_NN in_IN length_NN and_CC are_VBP found_VBN intracellularly_RB in_IN monocytes_NNS and_CC macrophages_NNS ._SENT In_IN preparations_NNS stained_VBN with_IN Giemsa_NP or_CC Leishman_NP stain_NN ,_, the_DT cytoplasm_NN appears_VBZ pale_JJ blue_NN ,_, with_IN a_DT relatively_RB large_JJ nucleus_NN that_WDT stains_VBZ red_JJ ._SENT In_IN the_DT same_JJ plane_NN as_IN the_DT nucleus_NN ,_, but_CC at_IN a_DT right_JJ angle_NN to_TO it_PP ,_, is_VBZ a_DT deep_JJ red_JJ or_CC violet_JJ rod-like_JJ body_NN called_VBD a_DT kinetoplast_NN ._SENT After_IN identification_NN ,_, parasite_NN density_NN can_MD be_VB scored_VBN microscopically_RB by_IN means_NNS of_IN a_DT logarithmic_JJ scale_NN ranging_VBG from_IN 0_CD (_( no_DT parasite_NN per_IN 1,000_CD oil_NN immersion_NN fields_NNS )_) to_TO +6_NN (_( >100_JJ parasites_NNS per_IN field_NN )_) ._SENT The_DT sensitivity_NN of_IN the_DT bone_NN marrow_NN smear_NN is_VBZ about_RB 60_CD to_TO 85_CD %_NN ._SENT Splenic_JJ aspirate_NN ,_, though_RB associated_VBN with_IN risk_NN of_IN fatal_JJ hemorrhage_NN in_IN inexperienced_JJ hands_NNS ,_, is_VBZ one_CD of_IN the_DT most_RBS valuable_JJ methods_NNS for_IN diagnosis_NN of_IN kala-azar_NN ,_, with_IN a_DT sensitivity_NN exceeding_VBG 95_CD %_NN ._SENT It_PP requires_VBZ no_DT special_JJ equipment_NN ,_, from_IN the_DT patient_NN 's_POS standpoint_NN is_VBZ generally_RB preferable_JJ to_TO the_DT more_RBR painful_JJ bone_NN marrow_NN aspirate_NN ,_, and_CC has_VBZ proven_VBN to_TO be_VB safe_JJ and_CC relatively_RB easy_JJ to_TO perform_VB in_IN experienced_JJ hands_NNS ._SENT For_IN patients_NNS suspected_VBN to_TO have_VB VL_NP ,_, splenic_JJ aspirate_NN can_MD be_VB performed_VBN even_RB when_WRB spleen_NN is_VBZ not_RB palpable_JJ ,_, after_IN demarcating_VBG the_DT area_NN of_IN splenic_JJ dullness_NN by_IN percussion_NN ._SENT The_DT only_JJ risk_NN of_IN splenic_JJ puncture_NN is_VBZ bleeding_VBG from_IN a_DT soft_JJ and_CC enlarged_JJ spleen_NN ._SENT At_IN our_PP$ treatment_NN center_NN ,_, fatal_JJ bleeding_NN has_VBZ occurred_VBN only_RB twice_RB in_IN 9,612_CD splenic_JJ aspirate_JJ procedures_NNS performed_VBN over_IN the_DT last_JJ 10_CD years_NNS ._SENT To_TO avoid_VB the_DT risk_NN of_IN excessive_JJ blood_NN loss_NN ,_, splenic_JJ puncture_NN should_MD be_VB avoided_VBN in_IN patients_NNS with_IN a_DT platelet_NN count_NN of_IN less_JJR than_IN 40,000_CD platelets/mul_NN and_CC a_DT prothrombin_NN time_NN of_IN more_JJR than_IN 5_CD s_NNS over_IN the_DT control_NN ._SENT A_DT tissue_NN specimen_NN ,_, e.g._FW ,_, a_DT spleen_NN ,_, liver_NN ,_, or_CC lymph_NN node_NN tissue_NN specimen_NN ,_, may_MD be_VB subjected_VBN to_TO imprint_VB cytology_NN by_IN the_DT repeated_JJ pressing_NN of_IN its_PP$ cut_NN flat_JJ surface_NN on_IN microscopic_JJ slides_NNS ._SENT The_DT smear_NN is_VBZ fixed_VBN with_IN absolute_JJ alcohol_NN and_CC stained_VBN with_IN Giemsa_NP stain_NN ._SENT In_IN imprint_NN cytology_NN ,_, a_DT monolayer_NN of_IN cells_NNS is_VBZ formed_VBN and_CC amastigotes_NNS are_VBP easily_RB identifiable_JJ ._SENT The_DT results_NNS are_VBP expressed_VBN as_IN the_DT number_NN of_IN leishmania_NN per_IN 100_CD host_NN cell_NN nuclei_NNS ._SENT Tissue_NN specimens_NNS can_MD also_RB be_VB subjected_VBN to_TO histology_NN ,_, and_CC the_DT presence_NN of_IN parasites_NNS can_MD be_VB demonstrated_VBN by_IN standard_JJ hematoxylin_NN and_CC eosin_NN stain_NN ._SENT Tissue_NN specimens_NNS are_VBP usually_RB uneven_JJ in_IN thickness_NN ;_: consequently_RB the_DT amastigotes_NNS are_VBP unevenly_RB distributed_VBN ._SENT Long_JJ searches_NNS may_MD be_VB required_VBN to_TO demonstrate_VB the_DT parasite_NN ._SENT The_DT sensitivity_NN of_IN the_DT test_NN can_MD be_VB increased_VBN by_IN staining_VBG the_DT specimen_NN with_IN fluorescent_JJ dye-tagged_JJ antibodies_NNS to_TO the_DT surface_NN receptors_NNS of_IN the_DT parasite_NN ._SENT Fluorescein_NN isothiocyanate_NN isomer-_NN or_CC rhodamide_NN B_NN isothiocyanate-conjugated_JJ antiserum_NN is_VBZ usually_RB used_VBN for_IN this_DT purpose_NN ._SENT Fluorescent_JJ dye-conjugated_JJ monoclonal_NN antibodies_NNS are_VBP also_RB used_VBN for_IN speciation_NN of_IN the_DT parasite_NN ._SENT Culture_NN of_IN parasite_NN can_MD improve_VB the_DT sensitivity_NN of_IN detection_NN of_IN parasite_NN ,_, but_CC leishmania_NN culture_NN is_VBZ rarely_RB needed_VBN in_IN routine_JJ clinical_JJ practice_NN ._SENT However_RB ,_, cultures_NNS are_VBP required_VBN for_IN (_( i_NP )_) obtaining_VBG a_DT sufficient_JJ number_NN of_IN organisms_NNS to_TO use_VB an_DT antigen_NN for_IN immunologic_JJ diagnosis_NN and_CC speciation_NN ,_, (_( ii_NNS )_) obtaining_VBG parasites_NNS to_TO be_VB used_VBN in_IN inoculating_VBG susceptible_JJ experimental_JJ animals_NNS ,_, (_( iii_NNS )_) in_IN vitro_NN screening_NN of_IN drugs_NNS ,_, and_CC (_( iv_NN )_) accurate_JJ diagnosis_NN of_IN the_DT infection_NN with_IN the_DT organism_NN (_( as_IN a_DT supplement_NN to_TO other_JJ methods_NNS or_CC to_TO provide_VB a_DT diagnosis_NN when_WRB routine_JJ methods_NNS have_VB failed_VBN )_) ._SENT Leishmania_NN strains_NNS can_MD be_VB maintained_VBN as_IN promastigotes_NNS in_IN artificial_JJ culture_NN medium_NN ._SENT The_DT culture_NN media_NNS used_VBN may_MD be_VB monophasic_JJ (_( Schneider_NP 's_POS insect_NN medium_NN ,_, M199_NP ,_, or_CC Grace_NP 's_POS medium_NN )_) or_CC diphasic_JJ (_( Novy-McNeal_NP Nicolle_NP medium_NN and_CC Tobies_NNS medium_NN )_) ._SENT We_PP prefer_VBP diphasic_JJ medium_NN containing_VBG modified_JJ diphasic_JJ rabbit_NN blood_NN agar_NN overlaid_VBN with_IN RPMI_NP 1640_CD (_( Gibco_NP BRL_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) for_IN primary_JJ isolation_NN ,_, and_CC we_PP prefer_VBP M199_JJ medium_NN containing_VBG 20_CD %_NN fetal_JJ calf_NN serum_NN to_TO amplify_VB parasite_NN numbers_NNS ._SENT Hockmeyer_NP 's_POS medium_NN ,_, which_WDT is_VBZ Schneider_NP 's_POS commercially_RB prepared_VBN culture_NN medium_NN supplemented_VBN with_IN 30_CD %_NN heat-inactivated_JJ fetal_JJ calf_NN serum_NN with_IN 100_CD IU_NP of_IN penicillin_NN and_CC 100_CD mug_NN of_IN streptomycin_NN ,_, is_VBZ simple_JJ to_TO use_VB and_CC satisfactory_JJ for_IN diagnosis_NN of_IN VL_NP ,_, but_CC it_PP is_VBZ expensive_JJ ._SENT Culture_NN tubes_NNS are_VBP inoculated_VBN with_IN 1_CD to_TO 2_CD drops_NNS of_IN bone_NN marrow_NN or_CC splenic_JJ aspirate_NN and_CC incubated_VBN at_IN a_DT temperature_NN between_IN 22_CD and_CC 28C_JJ ._SENT The_DT tubes_NNS are_VBP examined_VBN weekly_RB for_IN the_DT presence_NN of_IN promastigotes_NNS by_IN phase-contrast_JJ microscopy_NN or_CC by_IN wet_JJ mount_NN of_IN culture_NN fluid_NN for_IN 4_CD weeks_NNS before_IN being_VBG discarded_VBN as_IN negative_JJ ._SENT If_IN promastigotes_NNS are_VBP present_JJ ,_, they_PP are_VBP maintained_VBN by_IN weekly_JJ passage_NN to_TO fresh_JJ medium_NN ._SENT Blood_NN can_MD also_RB be_VB used_VBN to_TO isolate_VB the_DT parasite_NN ,_, but_CC the_DT method_NN is_VBZ slow_JJ and_CC takes_VBZ longer_RBR ._SENT Aseptically_RB collected_VBN blood_NN (_( 1_CD to_TO 2_CD ml_NN )_) is_VBZ diluted_VBN with_IN 10_CD ml_NN of_IN citrated_JJ saline_NN ,_, and_CC the_DT cellular_JJ deposit_NN obtained_VBN after_IN centrifugation_NN is_VBZ inoculated_VBN in_IN culture_NN media_NNS ._SENT Contamination_NN of_IN the_DT culture_NN media_NNS by_IN bacteria_NNS or_CC yeast_NN species_NNS or_CC other_JJ fungi_NNS usually_RB complicates_VBZ the_DT culture_NN but_CC can_MD be_VB avoided_VBN by_IN use_NN of_IN good_JJ sterile_JJ techniques_NNS and_CC by_IN the_DT addition_NN of_IN penicillin_NN (_( 200_CD IU/ml_NN )_) and_CC streptomycin_NN (_( 200_CD mug/ml_NN )_) to_TO the_DT medium_NN (_( for_IN bacteria_NNS )_) ,_, as_RB well_RB as_IN 5-flucytosine_JJ (_( 500_CD mug/ml_NN )_) (_( as_IN an_DT antimycotic_JJ agent_NN )_) ._SENT In_IN vitro_NN culture_NN of_IN the_DT amastigotes_NNS is_VBZ done_VBN for_IN chemotherapeutic_JJ studies_NNS and_CC to_TO study_VB the_DT interrelationship_NN of_IN the_DT amastigotes_NNS and_CC macrophages_NNS ._SENT The_DT amastigotes_NNS are_VBP grown_VBN in_IN tissue_NN or_CC macrophage_NN culture_NN ._SENT These_DT cell_NN lines_NNS are_VBP produced_VBN from_IN (_( i_NP )_) human_JJ peripheral_JJ blood_NN monocytes_NNS ,_, after_IN these_DT are_VBP set_VBN apart_RB by_IN density_NN sedimentation_NN with_IN lymphocyte_NN separation_NN medium_NN (_( LSM_NP ;_: Organon-Teknika_NP ,_, Durham_NP ,_, N.C._NP )_) ,_, in_IN which_WDT case_NN a_DT new_JJ batch_NN of_IN macrophages_NNS must_MD be_VB produced_VBN anew_RB ;_: (_( ii_NP )_) macrophage_NN cell_NN lines_NNS ,_, e.g._FW ,_, P388D_NP and_CC J774G8_NP lines_NNS from_IN mice_NNS ;_: and_CC (_( iii_NN )_) dog_NN sarcoma_NN and_CC hamster_NN peritoneal_JJ exudates_NNS of_IN cell_NN lines_NNS ,_, in_IN which_WDT case_NN continuous_JJ culture_NN can_MD be_VB achieved_VBN ._SENT The_DT parasite_NN can_MD also_RB be_VB demonstrated_VBN after_IN inoculation_NN of_IN laboratory_NN animals_NNS (_( such_JJ as_IN hamsters_NNS ,_, mice_NNS or_CC guinea_NN pigs_NNS )_) with_IN infected_JJ specimen_NN ._SENT Animal_JJ inoculation_NN is_VBZ not_RB usually_RB employed_VBN as_IN a_DT diagnostic_JJ test_NN ,_, since_IN several_JJ months_NNS may_MD be_VB required_VBN to_TO obtain_VB a_DT positive_JJ result_NN ._SENT Golden_JJ hamster_NN is_VBZ the_DT animal_NN of_IN choice_NN for_IN maintaining_VBG L._NP donovani_NP complex_NN ._SENT It_PP can_MD be_VB infected_VBN via_IN many_JJ routes_NNS ,_, including_VBG across_IN mucous_JJ membranes_NNS ,_, but_CC intraperitoneal_JJ and_CC intrasplenic_JJ routes_NNS are_VBP preferred_JJ ._SENT Both_DT amastigotes_NNS and_CC promastigotes_NNS can_MD infect_VB the_DT animal_NN ._SENT After_IN inoculation_NN ,_, the_DT animal_NN is_VBZ examined_VBN weekly_RB for_IN signs_NNS of_IN infection_NN ,_, such_JJ as_IN cutaneous_JJ lesions_NNS ,_, hepatosplenomegaly_RB ,_, or_CC metastatic_JJ lesions_NNS ._SENT Amastigotes_NNS can_MD be_VB harvested_VBN by_IN biopsy_NN from_IN the_DT spleen_NN and_CC the_DT liver_NN of_IN an_DT animal_NN that_WDT is_VBZ under_IN anesthesia_NN and_CC that_WDT is_VBZ allowed_VBN to_TO survive_VB following_VBG the_DT procedure_NN as_IN a_DT source_NN of_IN infective_JJ parasite_NN ._SENT In_IN the_DT absence_NN of_IN signs_NNS of_IN obvious_JJ infection_NN ,_, the_DT animal_NN is_VBZ generally_RB sacrificed_VBN after_IN 4_CD months_NNS ,_, at_IN which_WDT point_NN liver_NN and_CC spleen_NN samples_NNS are_VBP examined_VBN for_IN the_DT presence_NN of_IN the_DT parasite_NN ._SENT In_IN areas_NNS of_IN endemicity_NN ,_, recognition_NN of_IN species_NNS of_IN leishmania_NN is_VBZ rarely_RB required_VBN ._SENT However_RB ,_, identification_NN of_IN an_DT organism_NN to_TO the_DT species_NN level_NN is_VBZ helpful_JJ epidemiologically_RB and_CC is_VBZ also_RB important_JJ for_IN the_DT treatment_NN of_IN and_CC prognosis_NN determination_NN for_IN global_JJ travelers_NNS who_WP are_VBP not_RB immune_JJ to_TO the_DT parasite_NN and_CC tend_VBP to_TO develop_VB unusual_JJ manifestations_NNS of_IN the_DT disease_NN ._SENT Identification_NN of_IN species_NNS of_IN the_DT L._NP donovani_NN complex_NN is_VBZ particularly_RB difficult_JJ ,_, because_IN morphologically_RB the_DT species_NNS are_VBP almost_RB indistinguishable_JJ from_IN each_DT other_JJ ._SENT For_IN species-level_JJ identification_NN ,_, a_DT large_JJ amount_NN of_IN promastigotes_NNS is_VBZ obtained_VBN by_IN culture_NN of_IN the_DT organism_NN and_CC the_DT species-specific_JJ isoenzyme_NN pattern_NN is_VBZ analyzed_VBN by_IN cellulose_NN acetate_NN electrophoresis_NN ._SENT Typing_VBG of_IN washed_JJ live_JJ promastigotes_NNS by_IN direct_JJ agglutination_NN test_NN with_IN species-specific_JJ monoclonal_NN antibodies_NNS is_VBZ another_DT highly_RB sensitive_JJ taxonomic_JJ tool_NN frequently_RB utilized_VBN for_IN this_DT purpose_NN ._SENT Species-level_JJ identification_NN can_MD also_RB be_VB done_VBN by_IN analysis_NN of_IN amplified_VBN minicircle_NN kinetoplast_NN DNA_NP (_( KDNA_NP )_) ,_, by_IN choosing_VBG primers_NNS from_IN conserved_VBN regions_NNS of_IN different_JJ leishmania_NN species_NNS KDNA_NP minicircles_NNS ._SENT Yet_RB another_DT method_NN used_VBN for_IN identification_NN of_IN species_NNS of_IN leishmania_NN is_VBZ the_DT analysis_NN of_IN the_DT in_IN vitro_NP promastigotes_NP '_POS released_VBN antigenic_JJ factors_NNS ,_, which_WDT are_VBP different_JJ for_IN different_JJ leishmanial_NN species_NNS ._SENT Although_IN demonstration_NN of_IN even_RB a_DT single_JJ amastigote_NN upon_IN microscopic_JJ examination_NN of_IN tissue_NN smears_NNS or_CC multiple_JJ promastigotes_NNS in_IN cultures_NNS is_VBZ considered_VBN sufficient_JJ for_IN positive_JJ diagnosis_NN of_IN the_DT disease_NN ,_, the_DT sensitivity_NN of_IN the_DT tissue_NN examination_NN ,_, except_IN in_IN the_DT case_NN of_IN splenic_JJ aspirate_NN ,_, is_VBZ low_JJ ._SENT Moreover_RB ,_, the_DT procedure(s)_NN for_IN obtaining_VBG tissue_NN specimen(s)_NN is_VBZ traumatic_JJ and_CC associated_VBN with_IN considerable_JJ risk_NN ._SENT Identification_NN of_IN amastigotes_NNS requires_VBZ considerable_JJ expertise_NN and_CC training_NN and_CC is_VBZ subject_JJ to_TO the_DT ability_NN of_IN the_DT observer_NN ._SENT Besides_RB ,_, culturing_VBG parasites_NNS is_VBZ expensive_JJ and_CC time_NN consuming_NN and_CC requires_VBZ expertise_NN and_CC costly_JJ equipment_NN ,_, severely_RB restricting_VBG its_PP$ use_NN in_IN routine_JJ clinical_JJ practice_NN ._SENT DNA_NP detection_NN method_NN ._SENT |_SYM Due_JJ to_TO the_DT limitations_NNS inherent_JJ in_IN techniques_NNS used_VBN for_IN detection_NN of_IN parasites_NNS ,_, new_JJ approaches_NNS to_TO the_DT detection_NN of_IN parasites_NNS ,_, such_JJ as_IN DNA_NN hybridization_NN ,_, have_VBP been_VBN attempted_VBN since_IN the_DT early_JJ 1980s_NNS ._SENT Although_IN these_DT methods_NNS had_VBD considerable_JJ sensitivity_NN (_( detecting_VBG as_RB few_JJ as_IN 50_CD to_TO 100_CD parasites_NNS )_) ,_, their_PP$ potential_JJ use_NN in_IN routine_JJ diagnosis_NN is_VBZ hampered_VBN by_IN the_DT complex_JJ procedure_NN of_IN hybridization_NN ._SENT The_DT development_NN of_IN PCR_NP has_VBZ provided_VBN a_DT powerful_JJ approach_NN to_TO the_DT application_NN of_IN molecular_JJ biology_NN techniques_NNS to_TO the_DT diagnosis_NN of_IN leishmaniasis_NN ._SENT Primers_NNS designed_VBN to_TO amplify_VB conserved_VBN sequences_NNS found_VBN in_IN minicircles_NNS of_IN KDNA_NP of_IN leishmanias_NNS of_IN different_JJ species_NNS were_VBD tested_VBN in_IN various_JJ tissues_NNS of_IN relevance_NN ._SENT Such_PDT a_DT target_NN was_VBD eminently_RB suitable_JJ because_IN the_DT kinetoplast_NN is_VBZ known_VBN to_TO possess_VB thousands_NNS of_IN copies_NNS of_IN minicircle_NN DNA_NN ._SENT In_IN recent_JJ years_NNS ,_, PCR-based_JJ diagnostic_JJ methods_NNS with_IN a_DT wide_JJ range_NN of_IN sensitivities_NNS and_CC specificities_NNS have_VBP been_VBN described_VBN ._SENT In_IN a_DT study_NN reported_VBD from_IN Sudan_NP ,_, PCR_NP was_VBD found_VBN to_TO be_VB more_RBR sensitive_JJ than_IN microscopy_NN for_IN the_DT detection_NN of_IN Leishmania_NP parasites_NNS in_IN lymph_NN node_NN and_CC bone_NN marrow_NN aspirations_NNS ._SENT However_RB ,_, its_PP$ sensitivity_NN for_IN the_DT detection_NN of_IN Leishmania_NP DNA_NP in_IN the_DT blood_NN of_IN parasitologically_RB proven_VBN VL_NP cases_NNS was_VBD only_RB 70_CD %_NN ._SENT In_IN another_DT study_NN reported_VBD from_IN India_NP ,_, in_IN which_WDT a_DT species-specific_JJ primer_NN for_IN L._NP donovani_NP (_( LDI_NP primer_NN )_) was_VBD used_VBN ,_, the_DT sensitivity_NN of_IN PCR_NP with_IN whole_JJ blood_NN from_IN VL_NP patients_NNS was_VBD 96_CD %_NN and_CC Leishmania_NP DNA_NP was_VBD detected_VBN in_IN skin_NN specimens_NNS from_IN 45_CD of_IN 48_CD patients_NNS with_IN PKDL_NP (_( sensitivity_NN ,_, 93.8_CD %_NN )_) ._SENT A_DT PCR-enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) technique_NN using_VBG a_DT primer_NN that_WDT was_VBD able_JJ to_TO identify_VB 33_CD L._NP infantum_NN strains_NNS from_IN 19_CD different_JJ zymodemes_NNS has_VBZ been_VBN developed_VBN ._SENT It_PP has_VBZ a_DT sensitivity_NN higher_JJR than_IN that_IN of_IN other_JJ diagnostic_JJ techniques_NNS ,_, e.g._FW ,_, indirect_JJ fluorescent-antibody_NN (_( IFA_NP )_) test_NN ,_, parasite_NN culture_NN ,_, or_CC microscopy_NN ,_, and_CC was_VBD able_JJ to_TO detect_VB a_DT minimum_NN of_IN 0.1_CD promastigote_NN or_CC 1_CD fg_NN of_IN genomic_JJ material_NN ._SENT This_DT PCR-ELISA_NP technique_NN can_MD potentially_RB be_VB used_VBN for_IN diagnosis_NN of_IN VL_NP from_IN peripheral_JJ blood_NN samples_NNS ._SENT PCR_NP done_VBN from_IN blood_NN spots_NNS on_IN filter_NN paper_NN can_MD also_RB be_VB used_VBN as_IN a_DT screening_NN test_NN to_TO identify_VB Leishmania_NP infection_NN in_IN immunocompromised_JJ patients_NNS with_IN high_JJ parasite_NN loads_NNS in_IN peripheral_JJ blood_NN ._SENT The_DT sensitivity_NN of_IN this_DT technique_NN for_IN detecting_VBG leishmania_NN (_( 75_CD %_NN )_) was_VBD considerably_RB higher_JJR than_IN the_DT respective_JJ sensitivities_NNS of_IN microscopy_NN (_( 26.3_CD %_NN )_) and_CC blood_NN culture_NN (_( 42.3_CD %_NN )_) (_( 17_CD )_) ._SENT However_RB ,_, PCR_NP assay_NN with_IN buffy_JJ coat_NN preparations_NNS to_TO detect_VB Leishmania_NP was_VBD 10_CD times_NNS more_RBR sensitive_JJ than_IN that_IN with_IN whole-blood_NN preparations_NNS ,_, and_CC particularly_RB good_JJ results_NNS were_VBD obtained_VBN when_WRB proteinase_NN K-based_JJ methods_NNS were_VBD used_VBN ._SENT Proteinase_NN K-based_NP PCR_NP was_VBD able_JJ to_TO detect_VB 10_CD parasites/ml_NN ._SENT A_DT fluorescent_JJ DNA_NN probe_NN specific_JJ for_IN a_DT conserved_VBN region_NN of_IN the_DT small_JJ subunit_NN rRNA_NN gene_NN of_IN Leishmania_NP and_CC a_DT pair_NN of_IN flanking_VBG primers_NNS ,_, when_WRB used_VBN for_IN DNA_NN amplification_NN in_IN one_CD assay_NN ,_, proved_VBD to_TO be_VB a_DT highly_RB specific_JJ and_CC rapid_JJ diagnostic_JJ modality_NN to_TO detect_VB infection_NN with_IN Leishmania_NP ._SENT Using_VBG this_DT rapid_JJ fluorogenic_JJ PCR_NP technique_NN ,_, DNA_NP could_MD be_VB amplified_VBN from_IN 27_CD strains_NNS of_IN cultured_JJ Leishmania_NP ,_, and_CC the_DT turnaround_NN time_NN from_IN fresh_JJ human_JJ tissue_NN biopsy_NN to_TO test_NN result_NN was_VBD found_VBN to_TO be_VB less_JJR than_IN 24_CD h_NN ._SENT Besides_IN being_VBG a_DT highly_RB sensitive_JJ and_CC specific_JJ tool_NN for_IN diagnosis_NN of_IN both_DT VL_NP and_CC PKDL_NP and_CC a_DT useful_JJ method_NN for_IN species_NN identification_NN ,_, PCR_NP can_MD also_RB be_VB used_VBN to_TO distinguish_VB between_IN relapse_NN and_CC reinfection_NN in_IN treated_VBN VL_NN patients_NNS ._SENT Restriction_NN fragment_NN length_NN polymorphism_NN analysis_NN of_IN the_DT PCR-amplified_JJ minicircle_NN of_IN leishmanial_NN DNA_NN can_MD be_VB utilized_VBN for_IN this_DT purpose_NN ._SENT PCR_NP could_MD also_RB prove_VB to_TO be_VB an_DT important_JJ tool_NN in_IN assessing_VBG the_DT success_NN of_IN VL_NP treatment_NN :_: of_IN patients_NNS treated_VBN for_IN VL_NP who_WP tested_VBD negative_JJ by_IN PCR_NP with_IN lymph_NN node_NN tissue_NN ,_, none_NN relapsed_VBD or_CC developed_VBD PKDL_NP ,_, while_IN more_JJR than_IN half_NN of_IN patients_NNS who_WP tested_VBD positive_JJ by_IN PCR_NP with_IN lymph_NN node_NN tissue_NN either_CC relapsed_VBN or_CC developed_VBN PKDL_NP after_IN apparent_JJ cure_NN of_IN disease_NN following_VBG supervised_JJ treatment_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, a_DT substantial_JJ number_NN of_IN the_DT patients_NNS who_WP tested_VBD positive_JJ by_IN PCR_NP ,_, after_IN apparent_JJ cure_NN ,_, did_VBD not_RB relapse_VB or_CC develop_VB PKDL_NP ,_, a_DT result_NN that_WDT suggests_VBZ the_DT limitation_NN of_IN PCR_NP in_IN deciding_VBG the_DT end_NN point_NN of_IN treatment_NN ._SENT The_DT PCR_NP positivity_NN observed_VBD in_IN these_DT patients_NNS may_MD be_VB due_JJ to_TO nonviable_JJ parasite_NN ._SENT Similarly_RB ,_, PCR_NP results_NNS for_IN healthy_JJ endemic_JJ controls_NNS may_MD be_VB positive_JJ ,_, which_WDT may_MD lead_VB to_TO the_DT erroneous_JJ conclusion_NN that_IN they_PP suffer_VBP from_IN VL_NP ._SENT In_IN these_DT healthy_JJ endemic_JJ controls_NNS ,_, a_DT combination_NN of_IN direct_JJ agglutination_NN test_NN (_( DAT_NP )_) (_( which_WDT shows_VBZ low_JJ titers_NNS in_IN healthy_JJ endemic_JJ controls_NNS )_) and_CC PCR_NP may_MD be_VB helpful_JJ in_IN defining_VBG the_DT status_NN of_IN these_DT patients_NNS ._SENT Immunodiagnosis_NN ._SENT (_( i_NP )_) Antigen_NN detection_NN ._SENT |_SYM Antigen_NN detection_NN is_VBZ more_RBR specific_JJ than_IN antibody-based_JJ immunodiagnostic_JJ tests_NNS ._SENT This_DT method_NN is_VBZ also_RB useful_JJ in_IN the_DT diagnosis_NN of_IN disease_NN in_IN cases_NNS where_WRB there_EX is_VBZ deficient_JJ antibody_NN production_NN (_( as_IN in_IN AIDS_NP patients_NNS )_) ._SENT De_FW Colmenares_NP et_FW al._FW (_( 20_CD )_) from_IN Spain_NP have_VBP reported_VBN two_CD polypeptide_NN fractions_NNS of_IN 72-75_CD kDa_NN and_CC 123_CD kDa_NN in_IN the_DT urine_NN of_IN kala-azar_NN patients_NNS ._SENT The_DT sensitivities_NNS of_IN the_DT 72-75-kDa_NP fractions_NNS were_VBD 96_CD %_NN ,_, and_CC the_DT specificities_NNS were_VBD 100_CD %_NN ._SENT Besides_RB ,_, these_DT antigens_NNS were_VBD not_RB detectable_JJ within_IN 3_CD weeks_NNS of_IN anti-kala-azar_NN treatment_NN ,_, suggesting_VBG that_IN the_DT test_NN has_VBZ a_DT very_RB good_JJ prognostic_JJ value_NN ._SENT A_DT new_JJ latex_NN agglutination_NN test_NN (_( KATEX_NP )_) for_IN detecting_VBG leishmanial_NN antigen_NN in_IN urine_NN of_IN patients_NNS with_IN VL_NP has_VBZ showed_VBN sensitivities_NNS between_IN 68_CD and_CC 100_CD %_NN and_CC a_DT specificity_NN of_IN 100_CD %_NN in_IN preliminary_JJ trials_NNS ._SENT The_DT antigen_NN is_VBZ detected_VBN quite_RB early_RB during_IN the_DT infection_NN and_CC the_DT results_NNS of_IN animal_JJ experiments_NNS suggest_VBP that_IN the_DT amount_NN of_IN detectable_JJ antigen_NN tends_VBZ to_TO decline_VB rapidly_RB following_VBG chemotherapy_NN ._SENT The_DT test_NN performed_VBD better_JJR than_IN any_DT of_IN the_DT serological_JJ tests_NNS when_WRB compared_VBN to_TO microscopy_NN ._SENT Large_JJ field_NN trials_NNS are_VBP under_IN way_NN to_TO evaluate_VB its_PP$ utility_NN for_IN the_DT diagnosis_NN and_CC prognosis_NN of_IN VL_NP ._SENT (_( ii_NP )_) Antibody_NN detection_NN ._SENT |_SYM For_IN several_JJ decades_NNS ,_, nonspecific_JJ methods_NNS ,_, which_WDT depend_VBP upon_IN raised_VBN globulin_NN levels_NNS ,_, have_VBP been_VBN used_VBN in_IN the_DT diagnosis_NN of_IN VL_NP ._SENT Some_DT of_IN the_DT tests_NNS used_VBN for_IN detecting_VBG these_DT nonspecific_JJ immunoglobulins_NNS are_VBP Napier_NP 's_POS formol_NN gel_NN or_CC aldehyde_NN test_NN and_CC the_DT Chopra_NP antimony_NN test_NN ._SENT Since_IN these_DT tests_NNS depend_VBP upon_IN raised_VBN globulin_NN levels_NNS ,_, results_NNS can_MD be_VB positive_JJ in_IN a_DT host_NN of_IN conditions_NNS ._SENT Lack_NN of_IN specificity_NN ,_, as_RB well_RB as_IN varying_VBG sensitivities_NNS ,_, renders_VBZ them_PP highly_RB unreliable_JJ ._SENT Several_JJ immunodiagnostic_JJ methods_NNS which_WDT are_VBP more_RBR sensitive_JJ and_CC specific_JJ have_VBP been_VBN developed_VBN ._SENT They_PP are_VBP useful_JJ in_IN identifying_VBG specific_JJ cases_NNS and_CC can_MD be_VB used_VBN for_IN community_NN surveillance_NN ._SENT The_DT human_JJ body_NN makes_VBZ an_DT attempt_NN to_TO fight_VB against_IN VL_NP by_IN producing_VBG some_DT of_IN the_DT highest_JJS levels_NNS of_IN antibodies_NNS found_VBN in_IN response_NN to_TO any_DT disease_NN ,_, all_RB to_TO no_DT avail_NN ._SENT This_DT is_VBZ due_JJ to_TO polyclonal_JJ activation_NN of_IN the_DT B_NP cells_NNS ,_, resulting_VBG in_IN marked_JJ elevation_NN of_IN levels_NNS (_( in_IN serum_NN )_) of_IN immunoglobulin_NN G_NP (_( IgG_NP )_) and_CC IgM_NP against_IN various_JJ nonspecific_JJ proteins_NNS and_CC haptens_NNS ._SENT The_DT consistent_JJ presence_NN of_IN high_JJ levels_NNS of_IN antibodies_NNS against_IN parasite_NN antigens_NNS can_MD simplify_VB diagnosis_NN of_IN VL_NP ._SENT Several_JJ serological_JJ techniques_NNS are_VBP based_VBN on_IN detection_NN of_IN these_DT antibodies_NNS ._SENT The_DT specificity_NN of_IN the_DT antibody_NN depends_VBZ upon_IN the_DT antigen_NN or_CC epitope_NN used_VBN in_IN the_DT test_NN ,_, as_IN the_DT parasite_NN stimulates_VBZ production_NN of_IN a_DT wide_JJ array_NN of_IN antibodies_NNS ,_, including_VBG group-_NN ,_, genus-_NN ,_, and_CC species-specific_JJ antibodies_NNS ._SENT Therefore_RB ,_, the_DT sensitivity_NN may_MD depend_VB upon_IN the_DT test_NN and_CC its_PP$ methodology_NN ,_, but_CC the_DT specificity_NN will_MD depend_VB on_IN the_DT antigen_NN rather_RB than_IN the_DT serological_JJ procedure_NN used_VBD ._SENT In_IN most_JJS serological_JJ tests_NNS ,_, the_DT sensitivity_NN and_CC specificity_NN data_NNS are_VBP compared_VBN against_IN demonstration_NN of_IN parasites_NNS in_IN various_JJ tissues_NNS ._SENT Conventional_JJ methods_NNS for_IN antibody_NN detection_NN included_VBD gel_NN diffusion_NN ,_, complement_VB fixation_NN test_NN ,_, indirect_JJ hemagglutination_NN test_NN ,_, IFA_NP test_NN ,_, and_CC countercurrent_JJ immunoelectrophoresis_NN ._SENT However_RB ,_, aside_RB from_IN practical_JJ difficulties_NNS at_IN peripheral_JJ laboratories_NNS ,_, the_DT sensitivities_NNS and_CC specificities_NNS of_IN most_JJS of_IN the_DT above_JJ tests_NNS have_VBP been_VBN the_DT limiting_VBG factors_NNS ._SENT Except_IN for_IN the_DT IFA_NP test_NN ,_, which_WDT is_VBZ used_VBN on_IN a_DT limited_JJ scale_NN ,_, these_DT tests_NNS are_VBP rarely_RB used_VBN for_IN routine_JJ diagnosis_NN of_IN VL_NP ._SENT In_IN 1988_CD ,_, a_DT modified_JJ DAT_NP was_VBD reported_VBN to_TO be_VB useful_JJ in_IN kala-azar_NN and_CC is_VBZ being_VBG used_VBN in_IN several_JJ countries_NNS of_IN endemicity_NN ._SENT In_IN this_DT test_NN ,_, the_DT trypsinized_JJ whole_JJ promastigotes_NNS are_VBP formalin_NN fixed_VBN and_CC stained_VBN with_IN Coomasie_NP brilliant_JJ blue_NN ;_: serum_NN from_IN the_DT patient_NN is_VBZ then_RB incubated_VBN with_IN the_DT antigen_NN ,_, and_CC agglutination_NN is_VBZ observed_VBN the_DT next_JJ day_NN ._SENT Use_NN of_IN an_DT 0.8_CD %_NN concentration_NN of_IN 0.1_CD M_NN 2-mercaptoethanol_JJ in_IN the_DT sample_NN diluent_NN further_RBR improves_VBZ its_PP$ performance_NN ._SENT DAT_NP in_IN various_JJ studies_NNS has_VBZ shown_VBN to_TO be_VB 91_CD to_TO 100_CD %_NN sensitive_JJ and_CC 72_CD to_TO 100_CD %_NN specific_JJ ._SENT In_IN Sudan_NP ,_, in_IN specially_RB set_VBN up_RP field_NN laboratories_NNS ,_, Medecins_NP Sans_NP Frontieres_NP uses_VBZ DAT_NP for_IN diagnosis_NN of_IN VL_NP ;_: patients_NNS with_IN high_JJ titers_NNS receive_VBP treatment_NN ,_, and_CC a_DT confirmatory_JJ parasitic_JJ diagnosis_NN is_VBZ done_VBN in_IN those_DT with_IN low_JJ titers_NNS ._SENT From_IN India_NP ,_, several_JJ laboratories_NNS reported_VBD satisfactory_JJ sensitivity_NN and_CC specificity_NN levels_NNS for_IN this_DT test_NN ._SENT Although_IN DAT_NP showed_VBD a_DT high_JJ degree_NN of_IN repeatability_NN within_IN the_DT centers_NNS ,_, its_PP$ reproducibility_NN across_IN the_DT centers_NNS was_VBD quite_RB weak_JJ ._SENT Moreover_RB ,_, difficult_JJ field_NN conditions_NNS ,_, the_DT fragility_NN of_IN aqueous_JJ antigen_NN ,_, the_DT lack_NN of_IN cold_JJ chain_NN ,_, and_CC batch-to-batch_NN variations_NNS in_IN the_DT antigen_NN ,_, along_RB with_IN the_DT nonstandardization_NN of_IN test_NN readings_NNS ,_, have_VBP severely_RB limited_VBN its_PP$ widespread_JJ applicability_NN in_IN regions_NNS of_IN endemicity_NN ._SENT Freeze-dried_VBN antigens_NNS developed_VBN in_IN Belgian_JJ and_CC Dutch_JJ laboratories_NNS are_VBP likely_JJ to_TO overcome_VB some_DT of_IN these_DT handicaps_NNS ._SENT Unless_IN this_DT improved_VBN antigen_NN is_VBZ produced_VBN indigenously_RB to_TO make_VB it_PP affordable_JJ and_CC DAT_NP is_VBZ made_VBN user_NN friendly_JJ with_IN one-step_NN dilution_NN and_CC reduced_VBN incubation_NN time_NN ,_, its_PP$ field_NN use_NN is_VBZ unlikely_JJ in_IN countries_NNS of_IN endemicity_NN like_IN India_NP ._SENT Like_IN most_JJS antibody-based_JJ tests_NNS ,_, DAT_NP may_MD yield_VB positive_JJ results_NNS for_IN a_DT long_JJ time_NN after_IN complete_JJ cure_NN and_CC thus_RB has_VBZ not_RB proved_VBN to_TO be_VB of_IN much_JJ prognostic_JJ value_NN ._SENT ELISA_NP has_VBZ been_VBN used_VBN as_IN a_DT potential_JJ serodiagnostic_JJ tool_NN for_IN almost_RB all_DT infectious_JJ diseases_NNS ,_, including_VBG leishmaniasis_NN ._SENT The_DT technique_NN is_VBZ highly_RB sensitive_JJ ,_, but_CC its_PP$ specificity_NN depends_VBZ upon_IN the_DT antigen_NN used_VBD ._SENT Several_JJ antigens_NNS have_VBP been_VBN tried_VBN ._SENT The_DT commonly_RB used_VBN antigen_NN is_VBZ a_DT crude_JJ soluble_JJ antigen_NN (_( CSA_NP )_) ._SENT It_PP is_VBZ prepared_VBN by_IN repeated_JJ freezing_NN and_CC thawing_VBG (_( four_CD to_TO six_CD cycles_NNS )_) of_IN a_DT suspension_NN of_IN promastigotes_NNS in_IN phosphate-buffered_JJ saline_NN ,_, followed_VBN by_IN cold_JJ centrifugation_NN at_IN 10,000_CD to_TO 20,000_CD x_SYM g._FW The_DT supernatant_JJ is_VBZ used_VBN as_IN soluble_JJ antigen_NN and_CC is_VBZ used_VBN to_TO coat_VB ELISA_NP plates_NNS after_IN estimation_NN of_IN protein_NN content_NN (_( 100_CD to_TO 5,000_CD ng/ml_NNS )_) ._SENT The_DT sensitivity_NN of_IN ELISA_NP using_VBG these_DT concentrations_NNS of_IN CSA_NP is_VBZ reported_VBN to_TO range_VB from_IN 80_CD to_TO 100_CD %_NN ,_, but_CC cross-reactions_NNS with_IN sera_NN from_IN patients_NNS with_IN trypanosomiasis_NN ,_, tuberculosis_NN ,_, and_CC toxoplasmosis_NN have_VBP been_VBN recorded_VBN ._SENT On_IN the_DT other_JJ hand_NN ,_, when_WRB various_JJ selective_JJ antigenic_JJ masses_NNS (_( 116_CD kDa_NNS ,_, 72_CD kDa_NNS ,_, and_CC 66_CD kDa_NNS )_) were_VBD used_VBN ,_, a_DT specificity_NN of_IN 100_CD %_NN could_MD be_VB achieved_VBN ,_, but_CC only_RB at_IN the_DT cost_NN of_IN sensitivity_NN ,_, which_WDT went_VBD down_RP to_TO as_RB low_JJ as_IN 37.5_CD %_NN ._SENT Palatnik-de-Souza_NP et_FW al._FW described_VBD the_DT use_NN of_IN fucose-mannose_JJ ligand_NN as_IN the_DT antigenic_JJ molecule_NN ._SENT It_PP is_VBZ a_DT 36-kDa_JJ glycoprotein_NN present_NN throughout_IN the_DT life_NN cycle_NN of_IN leishmania_NN (_( amastigote_NN and_CC promastigote_NN stages_NNS )_) ._SENT Its_PP$ use_NN in_IN ELISA_NP has_VBZ been_VBN found_VBN to_TO result_VB in_IN 100_CD %_NN sensitivity_NN and_CC 96_CD %_NN specificity_NN ._SENT In_IN a_DT recent_JJ study_NN ,_, it_PP was_VBD found_VBN that_IN the_DT sensitivity_NN and_CC specificity_NN of_IN ELISA_NP in_IN diagnosing_VBG VL_NP could_MD also_RB be_VB increased_VBN by_IN the_DT use_NN of_IN soluble_JJ antigens_NNS derived_VBN from_IN promastigotes_NNS cultivated_VBN in_IN a_DT protein-free_JJ medium_NN ._SENT One_CD study_NN ,_, done_VBN with_IN 129_CD VL_NP and_CC 143_CD cutaneous_JJ leishmaniasis_NN patients_NNS ,_, showed_VBD a_DT sensitivity_NN of_IN 95_CD %_NN ._SENT A_DT recombinant_JJ antigen_NN ,_, rK39_NN ,_, has_VBZ been_VBN shown_VBN to_TO be_VB specific_JJ for_IN antibodies_NNS in_IN patients_NNS with_IN VL_NP caused_VBD by_IN members_NNS of_IN the_DT L._NP donovani_NN complex_NN ._SENT This_DT antigen_NN ,_, which_WDT is_VBZ conserved_VBN in_IN the_DT kinesin_NN region_NN ,_, is_VBZ highly_RB sensitive_JJ and_CC predictive_JJ of_IN the_DT onset_NN of_IN acute_JJ disease_NN ._SENT The_DT antigen_NN is_VBZ derived_VBN from_IN L._NP chagasi_NP ,_, which_WDT in_IN the_DT United_NP States_NPS is_VBZ used_VBN for_IN veterinary_JJ purposes_NNS ,_, though_IN it_PP is_VBZ not_RB approved_VBN for_IN human_JJ use_NN ._SENT High_JJ antibody_NN titers_NNS in_IN immunocompetent_JJ patients_NNS with_IN VL_NP have_VBP been_VBN demonstrated_VBN ._SENT This_DT antigen_NN has_VBZ been_VBN reported_VBN to_TO be_VB 100_CD %_NN sensitive_JJ and_CC 100_CD %_NN specific_JJ in_IN the_DT diagnosis_NN of_IN VL_NP and_CC PKDL_NP by_IN ELISA_NP ._SENT Another_DT important_JJ facet_NN of_IN anti-rK39_JJ antibody_NN is_VBZ that_IN the_DT titer_NN correlates_VBZ directly_RB with_IN the_DT disease_NN activity_NN ,_, indicating_VBG its_PP$ potential_NN for_IN use_NN in_IN predicting_VBG response_NN to_TO chemotherapy_NN ._SENT It_PP was_VBD previously_RB shown_VBN that_IN anti-rK39_JJ antibody_NN titers_NNS were_VBD 59-fold_NN higher_JJR than_IN those_DT of_IN antibody_NN against_IN CSA_NP at_IN the_DT time_NN of_IN diagnosis_NN ,_, and_CC with_IN successful_JJ therapy_NN ,_, it_PP fell_VBD sharply_RB at_IN the_DT end_NN of_IN treatment_NN and_CC fell_VBD further_JJR during_IN follow-up_NN monitoring_NN ._SENT In_IN patients_NNS who_WP experience_VBP disease_NN relapse_NN ,_, the_DT titer_NN rose_VBD steeply_RB again_RB ._SENT The_DT diagnostic_JJ and_CC prognostic_JJ utility_NN of_IN rK39_NN for_IN HIV-infected_JJ patients_NNS has_VBZ also_RB been_VBN demonstrated_VBN ._SENT Because_IN of_IN the_DT conditions_NNS prevailing_VBG in_IN areas_NNS of_IN endemicity_NN ,_, any_DT sophisticated_JJ method_NN cannot_MD be_VB employed_VBN on_IN a_DT wider_JJR scale_NN ._SENT There_EX is_VBZ a_DT need_NN for_IN a_DT simple_JJ rapid_JJ and_CC accurate_JJ test_NN with_IN good_JJ sensitivity_NN and_CC specificity_NN ,_, which_WDT can_MD be_VB used_VBN without_IN any_DT specific_JJ expertise_NN ._SENT A_DT promising_JJ ready-to-use_NN immunochromatographic_JJ strip_NN test_NN based_VBN on_IN rK39_JJ antigen_NN has_VBZ been_VBN developed_VBN as_IN a_DT rapid_JJ test_NN for_IN use_NN in_IN difficult_JJ field_NN conditions_NNS ._SENT The_DT recombinant_JJ antigen_NN is_VBZ immobilized_VBN on_IN a_DT small_JJ rectangular_JJ piece_NN of_IN nitrocellulose_NN membrane_NN in_IN a_DT band_NN form_NN ,_, and_CC goat_NN anti-protein_NP A_NP is_VBZ attached_VBN to_TO the_DT membrane_NN above_IN the_DT antigen_NN band_NN ._SENT After_IN the_DT finger_NN is_VBZ pricked_VBN ,_, half_PDT a_DT drop_NN of_IN blood_NN is_VBZ smeared_VBN at_IN the_DT tip_NN of_IN the_DT strip_NN ,_, and_CC the_DT lower_JJR end_NN of_IN the_DT strip_NN is_VBZ allowed_VBN to_TO soak_VB in_IN 4_CD to_TO 5_CD drops_NNS of_IN phosphate-buffered_JJ saline_NN ,_, placed_VBN on_IN a_DT clean_JJ glass_NN slide_NN or_CC tube_NN ._SENT If_IN the_DT antibody_NN is_VBZ present_JJ ,_, it_PP will_MD react_VB with_IN the_DT conjugate_JJ (_( protein_NN A_DT colloidal_JJ gold_NN )_) that_WDT is_VBZ predried_VBN on_IN the_DT assay_NN strip_NN ._SENT The_DT mixture_NN moves_VBZ along_IN the_DT strip_NN by_IN capillary_JJ action_NN and_CC reacts_VBZ with_IN rK39_JJ antigen_NN on_IN the_DT strip_NN ,_, yielding_VBG a_DT pink_JJ band_NN ._SENT In_IN the_DT strip_NN of_IN patients_NNS who_WP are_VBP infected_JJ ,_, two_CD pinkish_JJ lines_NNS appear_VBP in_IN the_DT middle_NN of_IN the_DT nitrocellulose_NN membrane_NN (_( the_DT upper_JJ pinkish_JJ band_NN serves_VBZ as_IN a_DT procedural_JJ control_NN )_) ._SENT In_IN the_DT first_JJ extensive_JJ field_NN trial_NN in_IN 323_CD patients_NNS ,_, we_PP found_VBD the_DT strip_NN test_NN to_TO be_VB 100_CD %_NN sensitive_JJ (_( confidence_NN interval_NN ,_, 98_CD to_TO 100_CD %_NN )_) and_CC 98_CD %_NN specific_NN (_( confidence_NN interval_NN ,_, 95_CD to_TO 100_CD %_NN )_) ._SENT Several_JJ studies_NNS from_IN the_DT Indian_JJ subcontinent_NN reported_VBD the_DT test_NN to_TO be_VB 100_CD %_NN sensitive_JJ ._SENT However_RB ,_, when_WRB evaluated_VBN in_IN Sudan_NP ,_, the_DT sensitivity_NN of_IN the_DT test_NN was_VBD only_RB 67_CD %_NN ._SENT In_IN the_DT Sudan_NP study_NN ,_, all_PDT the_DT parasitologically_RB confirmed_VBN VL_NP patients_NNS who_WP tested_VBD negative_JJ by_IN the_DT rK39_JJ strip_NN test_NN showed_VBD IgG_NP against_IN rK39_NN by_IN micro-ELISA_NN (_( though_IN at_IN lower_JJR titers_NNS )_) ._SENT In_IN a_DT study_NN done_VBN in_IN southern_JJ Europe_NP ,_, the_DT rK39_JJ strip_NN test_NN results_NNS were_VBD positive_JJ in_IN only_RB 71.4_CD %_NN of_IN the_DT cases_NNS of_IN VL_NP ._SENT These_DT differences_NNS in_IN sensitivity_NN may_MD be_VB due_JJ to_TO differences_NNS in_IN the_DT antibody_NN responses_NNS observed_VBN in_IN different_JJ ethnic_JJ groups_NNS ._SENT When_WRB tested_VBN for_IN PKDL_NP ,_, the_DT test_NN had_VBD a_DT 91_CD %_NN sensitivity_NN ._SENT High_JJ levels_NNS of_IN specificity_NN (_( 97_CD to_TO 100_CD %_NN )_) have_VBP been_VBN reported_VBN uniformly_RB for_IN this_DT test_NN ;_: however_RB ,_, with_IN a_DT later_JJR version_NN of_IN the_DT rK39-treated_JJ strips_NNS ,_, some_DT (_( 12.5_CD %_NN )_) healthy_JJ endemic_JJ control_NN subjects_NNS also_RB tested_VBD positive_JJ ._SENT While_IN such_JJ reactions_NNS might_MD be_VB considered_VBN to_TO be_VB false_RB positive_JJ ,_, these_DT probably_RB represent_VBP subclinical_JJ infections_NNS :_: PCR_NP assay_NN for_IN L._NP donovani_NP was_VBD positive_JJ in_IN a_DT few_JJ of_IN these_DT cases_NNS ._SENT Anti-rK39_NP IgG_NP may_MD be_VB present_JJ in_IN serum_NN for_IN an_DT extended_JJ period_NN after_IN successful_JJ treatment_NN for_IN VL_NP ;_: thus_RB ,_, patients_NNS with_IN suspected_JJ relapse_NN of_IN VL_NP with_IN a_DT past_JJ history_NN of_IN infection_NN would_MD not_RB be_VB candidates_NNS for_IN diagnosis_NN by_IN strip_NN testing_NN ._SENT Another_DT drawback_NN of_IN this_DT format_NN is_VBZ that_IN an_DT individual_NN with_IN a_DT positive_JJ rK39_NN strip_NN test_NN result_NN may_MD suffer_VB from_IN an_DT illness(es)_NN (_( malaria_NN ,_, typhoid_JJ fever_NN ,_, or_CC tuberculosis_NN )_) with_IN clinical_JJ features_NNS similar_JJ to_TO those_DT of_IN VL_NP yet_RB be_VB misdiagnosed_VBN as_IN suffering_NN from_IN VL_NP ._SENT Notwithstanding_IN these_DT limitations_NNS ,_, the_DT rK39_JJ immunochromatographic_JJ strip_NN test_NN has_VBZ proved_VBN to_TO be_VB versatile_JJ in_IN predicting_VBG acute_JJ infection_NN ,_, and_CC it_PP is_VBZ the_DT only_RB available_JJ format_NN for_IN diagnosis_NN of_IN VL_NP with_IN acceptable_JJ sensitivity_NN and_CC specificity_NN levels_NNS which_WDT is_VBZ also_RB inexpensive_JJ (_( similar1_JJ to_TO 1.5_CD U.S._NP dollars_NNS )_) and_CC simple_JJ and_CC can_MD be_VB performed_VBN even_RB by_IN paramedics_NN in_IN prevailing_VBG difficult_JJ field_NN conditions_NNS ._SENT Specific_JJ antibodies_NNS can_MD also_RB be_VB detected_VBN by_IN Western_NP blotting_VBG ._SENT For_IN this_DT type_NN of_IN testing_NN ,_, promastigotes_NNS of_IN L._NP donovani_NNS are_VBP grown_VBN to_TO log_VB phase_NN and_CC lysed_VBN and_CC the_DT soluble_JJ protein_NN is_VBZ run_VBN on_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN gels_NNS ._SENT The_DT separated_JJ proteins_NNS are_VBP electroblotted_VBN onto_IN a_DT nitrocellulose_NN membrane_NN and_CC probed_VBN with_IN serum_NN from_IN the_DT patient_NN ._SENT The_DT sensitivity_NN of_IN this_DT technique_NN can_MD be_VB enhanced_VBN using_VBG the_DT chemiluminescent_JJ antibody_NN probes_NNS ._SENT Using_VBG Western_JJ blotting_VBG ,_, one_PP can_MD find_VB even_RB minor_JJ antigenic_JJ differences_NNS among_IN various_JJ organisms_NNS and_CC thus_RB detect_VB cross-reactive_JJ antigens_NNS ._SENT However_RB ,_, the_DT process_NN is_VBZ time_NN consuming_NN ,_, technically_RB cumbersome_JJ ,_, and_CC expensive_JJ ._SENT (_( iii_NP )_) Skin_NP testing_NN ._SENT |_SYM Delayed_NP type_NN hypersensitivity_NN (_( DTH_NP )_) or_CC T-cell-mediated_JJ immunity_NN is_VBZ a_DT group-specific_JJ immune_JJ response_NN ._SENT The_DT Montenegro_NP skin_NN test_NN (_( leishmanin_NN skin_NN test_NN )_) is_VBZ a_DT test_NN for_IN DTH_NP specific_JJ to_TO leishmaniasis_NN ,_, but_CC its_PP$ role_NN is_VBZ limited_VBN ._SENT In_IN this_DT method_NN ,_, 0.5_CD ml_NN of_IN phenol-killed_JJ whole_JJ parasites_NNS (_( 5_CD x_SYM 107_CD promastigotes_NNS )_) is_VBZ injected_VBN on_IN the_DT volar_JJ aspect_NN of_IN the_DT forearm_NN of_IN the_DT patient_NN ._SENT After_IN 48_CD to_TO 72_CD h_NN ,_, the_DT size_NN of_IN induration_NN is_VBZ measured_VBN and_CC compared_VBN with_IN the_DT size_NN of_IN induration_NN produced_VBN by_IN injection_NN of_IN a_DT phenol-saline_NN control_NN in_IN the_DT other_JJ forearm_NN ._SENT Presently_RB ,_, there_EX is_VBZ no_DT available_JJ standardized_JJ leishmanin_NN reagent_NN ._SENT All_DT leishmanins_NNS are_VBP said_VBN to_TO be_VB alike_JJ and_CC nonspecific_JJ ._SENT The_DT test_NN is_VBZ negative_JJ in_IN acute_JJ cases_NNS of_IN VL_NP due_JJ to_TO the_DT absence_NN of_IN DTH_NP and_CC is_VBZ positive_JJ only_RB in_IN cases_NNS where_WRB kala-azar_NN has_VBZ been_VBN cured_VBN ._SENT FIG._NN 1_CD ._SENT |_SYM Microphotograph_NN showing_VBG intracellular_JJ and_CC extracellular_JJ L._NP donovani_NP Microphotograph_NP showing_VBG intracellular_JJ and_CC extracellular_JJ L._NP donovani_NN bodies_NNS in_IN splenic_JJ aspirate_NN from_IN a_DT patient_NN with_IN visceral_JJ leishmaniasis_NN ._SENT LEISHMANIA_NN COINFECTION_NN :_: Atypical_JJ clinical_JJ presentations_NNS of_IN VL_NP in_IN HIV-infected_JJ patients_NNS pose_VBP a_DT considerable_JJ diagnostic_JJ challenge_NN ._SENT In_IN fact_NN ,_, the_DT clinical_JJ triad_NN of_IN fever_NN ,_, splenomegaly_NN ,_, and_CC hepatomegaly_RB is_VBZ found_VBN in_IN less_JJR than_IN half_NN of_IN such_JJ patients_NNS ,_, though_RB more_RBR so_RB in_IN patients_NNS with_IN low_JJ CD4_NP counts_NNS (_( <50_NP CD4_NP cells/mm3_NN )_) ._SENT In_IN these_DT patients_NNS ,_, leishmaniasis_NN can_MD present_VB with_IN gastrointestinal_JJ involvement_NN (_( stomach_NN ,_, duodenum_NN ,_, or_CC colon_NN )_) ;_: ascites_NN ;_: pleural_JJ or_CC pericardial_JJ effusion_NN ;_: involvement_NN of_IN lungs_NNS ,_, tonsils_NNS ,_, and_CC skin_NN ;_: and_CC even_RB as_RB widely_RB disseminated_VBN disease_NN ._SENT The_DT diagnostic_JJ principles_NNS remain_VBP essentially_RB the_DT same_JJ as_IN those_DT for_IN non-HIV-infected_NP patients_NNS ._SENT The_DT presence_NN of_IN amastigotes_NNS may_MD be_VB demonstrated_VBN in_IN buffy_JJ coat_NN preparation_NN ._SENT Sometimes_RB the_DT presence_NN of_IN amastigotes_NNS in_IN unusual_JJ sites_NNS may_MD be_VB demonstrated_VBN (_( e.g._FW ,_, amastigotes_NNS may_MD be_VB present_JJ in_IN specimens_NNS from_IN bronchoalveolar_JJ lavage_NN ,_, pleural_JJ fluid_NN ,_, or_CC biopsy_NN specimens_NNS from_IN the_DT gastrointestinal_JJ tract_NN )_) ._SENT For_IN HIV_NP patients_NNS ,_, the_DT sensitivity_NN of_IN antibody-based_JJ immunologic_JJ tests_NNS like_IN the_DT IFA_NP test_NN and_CC ELISA_NP is_VBZ low_JJ ._SENT Since_IN the_DT parasite_NN load_NN is_VBZ quite_RB heavy_JJ in_IN these_DT patients_NNS ,_, the_DT presence_NN of_IN leishmania_NN amastigotes_NNS in_IN the_DT bone_NN marrow_NN can_MD often_RB be_VB demonstrated_VBN ,_, but_CC there_EX are_VBP well-described_JJ instances_NNS in_IN the_DT literature_NN where_WRB amastigotes_NNS were_VBD not_RB demonstrable_JJ on_IN bone_NN marrow_NN ,_, though_IN they_PP were_VBD found_VBN at_IN unexpected_JJ locations_NNS like_IN the_DT stomach_NN ,_, the_DT colon_NN ,_, or_CC the_DT lungs_NNS ._SENT PCR_NP analysis_NN of_IN the_DT whole_JJ blood_NN or_CC its_PP$ buffy_JJ coat_NN preparation_NN may_MD prove_VB a_DT useful_JJ screening_NN test_NN for_IN these_DT patients_NNS ,_, obviating_VBG the_DT need_NN for_IN traumatic_JJ procedures_NNS ._SENT Various_JJ noninvasive_JJ tests_NNS ,_, with_IN various_JJ specificities_NNS and_CC sensitivities_NNS ,_, are_VBP available_JJ for_IN the_DT diagnosis_NN of_IN leishmaniasis_NN ;_: however_RB ,_, none_NN have_VBP become_VBN popular_JJ in_IN areas_NNS of_IN endemicity_NN ._SENT Very_RB few_JJ are_VBP commercially_RB available_JJ ;_: generally_RB speaking_VBG ,_, they_PP also_RB are_VBP expensive_JJ ,_, require_VB skilled_JJ personnel_NNS ,_, expensive_JJ equipment_NN ,_, and_CC electricity_NN ,_, and_CC are_VBP technically_RB demanding_VBG ._SENT Parasite_NN diagnosis_NN by_IN splenic_JJ ,_, marrow_NN ,_, or_CC skin_NN lesion_NN remains_VBZ the_DT "_`` gold_JJ standard_NN ,_, "_'' with_IN its_PP$ usual_JJ limitations_NNS ._SENT DAT_NP can_MD be_VB performed_VBN only_RB in_IN a_DT few_JJ centralized_JJ laboratories_NNS that_WDT are_VBP equipped_VBN for_IN the_DT purpose_NN (_( and_CC have_VBP trained_VBN personnel_NNS )_) ;_: cost_VB ,_, multiple_JJ steps_NNS ,_, incubation_NN ,_, and_CC antigenic_JJ variations_NNS are_VBP limiting_VBG factors_NNS ._SENT The_DT rK39_JJ strip_NN test_NN has_VBZ the_DT potential_NN to_TO be_VB used_VBN for_IN diagnosis_NN of_IN VL_NP under_IN field_NN conditions_NNS ._SENT Other_JJ tests_NNS ,_, which_WDT are_VBP likely_JJ candidates_NNS for_IN diagnosis_NN and_CC prognosis_NN of_IN leishmaniasis_NN in_IN the_DT future_NN ,_, are_VBP KATEX_NP and_CC a_DT field-adaptable_JJ version_NN of_IN PCR_NP ,_, which_WDT would_MD be_VB simple_JJ ,_, inexpensive_JJ ,_, and_CC easily_RB available_JJ ._SENT TABLE_NN 1_CD |_SYM Sensitivities_NNS and_CC specificities_NNS of_IN various_JJ methods_NNS used_VBN for_IN diagnosis_NN of_IN visceral_JJ leishmaniasis_NN 